Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salmeterol/fluticasone DPI HEXAL versus Seretide Accuhaler in moderate-to-severe persistent asthma
2007-005620-32Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salmeterol and fluticasone propionate in asthma and persistent asthma (2 arms), sponsored by Hexal AG. Primary endpoints: Absolute change in FEV1 from baseline to Week 12 and FEV1 AUC0-12 after 12 weeks relative to baseline FEV1. Started Mar 2009; status: completed.
02
Drugs
salmeterolfluticasone propionate
03
Conditions
asthmapersistent asthma
Beyond the preview
Go deeper on 2007-005620-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005620-32.